REPLIMUNE GROUP, INC. (REPL) Debt Components
- 2026-06-30: Long-term Debt, Excluding Current MaturitiesUSD $84.11M; Long-term DebtUSD (m); Commercial Paper, at Carrying ValueUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2026-03-31: Long-term Debt, Excluding Current MaturitiesUSD $83.31M; Long-term DebtUSD (m); Commercial Paper, at Carrying ValueUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-12-31: Long-term Debt, Excluding Current MaturitiesUSD $47.63M; Long-term DebtUSD (m); Commercial Paper, at Carrying ValueUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
- 2025-09-30: Long-term Debt, Excluding Current MaturitiesUSD $47.21M; Long-term DebtUSD (m); Commercial Paper, at Carrying ValueUSD (m); Long-Term Debt, Maturity, Year TwoUSD (m).
REPLIMUNE GROUP, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Commercial Paper, at Carrying Value USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount, Noncurrent USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $84.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $83.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $47.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $47.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $46.79M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $46.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $45.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $45.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $45.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $44.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $44.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $29.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $28.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $28.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $28.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $28.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $9.83M | (m) | $5.72M | $4.28M | (m) | (m) | $10.00M | $173.00K |
| 2020-06-30 | (m) | $9.76M | (m) | $5.72M | $4.28M | (m) | (m) | $10.00M | $236.00K |
| 2020-03-31 | (m) | $9.80M | (m) | (m) | (m) | (m) | (m) | $10.00M | $199.00K |
| 2020-03-31 | (m) | (m) | (m) | $527.00K | $6.56M | $2.92M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $9.74M | (m) | (m) | $527.00K | $6.56M | $2.92M | $10.00M | $261.00K |
| 2019-09-30 | (m) | $9.66M | (m) | (m) | $527.00K | $6.56M | $2.92M | $10.00M | $341.00K |
| 2018-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $4.99M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |